Granules India received ANDA approval for Sildenafil for oral suspension
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
The product is expected to be launched in FY25
Almost 300 million people globally have chronic hepatitis B
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
The Product will be manufactured at the company's facility in Bengaluru
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
Subscribe To Our Newsletter & Stay Updated